Reslizumab
Based on 1 Customer Validation
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.4%
- CAS. Nr.: 241473-69-8
- Molecular Weight:143.8 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Human IgG4 kappa
Human
|
IL-5 91.1 pM (IC50) |
Reslizumab (Sch 55700) (0-10 nM, 48 h) inhibits IL-5-dependent cell proliferation, with an IC50 value of approximately 91.1pM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human erythroleukemic TF-1 cell line
-
Concentration:0-10 nM
-
Incubation Time:48 h
-
Result:Showed antiproliferative activity with an IC50 of 91.1 pM.
Reslizumab (0.03-30 mg/kg; i.p.) inhibits both the pulmonary eosinophilia and airway hyperresponsiveness, and at 30 mg/kg, i.p. inhibits allergic, but not histamine-induced bronchoconstriction in allergic guinea pigs[3].
Reslizumab (0.1-1 mg/kg; i.p.) blocks the pulmonary eosinophilia and neutrophilia caused by tracheal injection of hIL-5 in guinea pigs[3].
Reslizumab (0.3 mg/kg; i.v.) blocks the pulmonary eosinophilia caused by antigen challenge for up to six months in allergic cynomolgus monkeys[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male B6D2F1/J mice weighing 20−25 g, sensitized by an intraperitoneal injection of 0.5 ml of alum-precipitated antigen (8 µg of ovalbumin (OVA) adsorbed to 2 mg of aluminum hydroxide gel in saline vehicle)[3]
-
Dosage:0−10 mg/kg
-
Administration:Intraperitoneal or intramuscular injection (For studies involving i.p. dose-response and i.m. evaluation, the antibody was given 2 h before OVA challenge. For experiments involving duration of activity, the antibody was given at times of 2 h or 4, 6, 8 or 12 weeks before antigen challenge.)
-
Result:Inhibited the influx of eosinophils into the lungs for a long time (up to 8 weeks after administration of 10 mg/kg and for up to 4 weeks after administration of 2 mg/kg. Demonstrated an anti-inflammatory activity that was additive to that of oral Prednisolone (HY-17463).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Dose-response curves showing inhibition of the binding of IL-5R alpha Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78162) to IL-5 Protein, Human (HEK293, His, HY-P70612) by Reslizumab. The EC50 for this effect is 382.2 ng/mL.
Chemical Information
-
CAS. Nr. 241473-69-8
-
Appearance Liquid
-
Molecular Weight 143.8 kDa
-
Color Colorless to light yellow
-
SMILES
[Reslizumab]
-
Synonyms
Sch 55700; CDP-835; JES1-39D10
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (261 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Liddament M, et al. Higher Binding Affinity and in vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab. Allergy Asthma Immunol Res. 2019 Mar;11(2):291-298. [Content Brief]
[2]. Pérez de Llano LA, et al. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab. Allergy. 2019 Sep 4. [Content Brief]
[3]. Egan RW, Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung. 1999 Sep;49(9):779-90. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reslizumab Related Classifications
HY-P9949 Related Classifications
Powered by Bioz